are pharmacies still compound tirzepatide FDA Says Compounding Can Keep Making Med The pharmaceutical manufacturers of both

Getting the reconstitution process wrong can compromise product stability, reduce therapeutic efficacy, and waste valuable materials

Lipodystrophy affects medication absorption and can make future injections more painful

Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss

The Innovation, 2(1), 100150

10.1016/S2213-8587(19)30002-6 81 LundgrenJ

PlexusDx prescribes compounded semaglutide injections from licensed 503A pharmacies with flat monthly pricing ($189/mo minimum) and no flat per-compound pricing changes